Abbvie’s Viekira Pak Costs $6.5 Million a Year in Avoidable Costs, Puts Patients at Greater Risk
Abbvie’s Viekira Pak Costs $6.5 Million a Year in Avoidable Costs, Puts Patients at Greater Risk// // In January 2015, Advera Health released a Drug Safety Monitor analysis comparing the safety of then newly approved Hepatitis C drugs Viekira Pak to Harvoni and Solvaldi (hereafter just Harvoni). Our analysts concluded, …both Harvoni and Sovaldi appear […]
